News & Updates
Filter by Specialty:
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
In the exploratory analyses of the phase III ASCEMBL trial, individuals with chronic myeloid leukaemia in chronic phase (CML-CP) who have failed ≥2 prior tyrosine kinase inhibitors (TKIs) continued to achieve deep responses with asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP).
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
04 Aug 2023
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023
Abrocitinib effectively controls AD regardless of dosing regimen
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
